Fig. 4
From: Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer
Antitumor effects of MSLN-CAR T cells on ovarian cancer cell xenografts in vivo. A Gating strategy of flow cytometry to discriminate TN, TCM, TEM, and TEMRA cells. B Flow cytometry was used to analyze the percentages of Tcm and TemT cell subsets in various CARs, with results reported as mean ± SD, ns means no significance. C NCG mice were intraperitoneally injected with 5 × 105 OVCAR3 cells and imaged on the fifth day. Next, BLI of tumor progression of representative mice receiving intraperitoneally injected or intravenously (tail vein) injected MSLN-CAR T cells, compared to control (CD19-CAR T cell treated) mice. D Quantification of tumor bioluminescence levels at different time points (n = 4 mice per group). (E) Quantification of body weights of mice receiving receiving intraperitoneally injected or intravenously (tail vein) injected MSLN-CAR T cells or CD19-CAR T cells. The experiments were repeated twice, independently, with similar results